Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.